Novartis plots more than 100 layoffs in New Jersey as part of rework to Xolair, cancer combo field sales teams

While Novartis has largely wrapped up its transformation into a leaner innovative medicines company—which included multiple rounds of staff cuts over the years—employment changes are still afoot at the Swiss pharma giant.

Take, for instance, a fresh round of layoffs in New Jersey, which offers the latest tell that the company is prepping to prioritize a new generation of drugs.